Trial Profile
A prospective, randomised, multicentre, open label phase III study of active specific immunotherapy with racotumomab plus best support treatment versus best support treatment in patients with advanced non-small cell lung cancer (NSCLC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 31 May 2022
Price :
$35
*
At a glance
- Drugs Racotumomab (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms PROACTIVE
- Sponsors Recombio
- 18 Sep 2018 Results published in the Journal of Clinical Oncology
- 06 Sep 2018 According to an Ariana Pharma media release, Recombio have an ongoing collaboration to apply KEM (Knowledge Extraction and Management) patient stratification technology to identify patients from the PROACTIVE clinical trial most benefiting from Racotumomab.
- 28 Jul 2016 Status changed from recruiting to active, no longer recruiting.